Freeline Therapeutics Holdings Plc
Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $14.47 million
- Book Value:
- Revenue TTM:
- Operating Margin TTM:
- Gross Profit TTM:
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
Freeline Therapeutics Holdings Plc had its IPO on 2020-08-07 under the ticker symbol FRLN.
The company operates in the Healthcare sector and Biotechnology industry. Freeline Therapeutics Holdings Plc has a staff strength of 152 employees.
Shares of Freeline Therapeutics Holdings Plc opened at $3.52 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $3.37 - $3.53, and closed at $3.52.
This is a -1.95% slip from the previous day's closing price.
A total volume of 1,397 shares were traded at the close of the day’s session.
In the last one week, shares of Freeline Therapeutics Holdings Plc have increased by +6.34%.
Freeline Therapeutics Holdings Plc's Key Ratios
Freeline Therapeutics Holdings Plc has a market cap of $14.47 million, indicating a price to book ratio of 0.559 and a price to sales ratio of 0.
In the last 12-months Freeline Therapeutics Holdings Plc’s revenue was $617000 with a gross profit of $0 and an EBITDA of $-75692000. The EBITDA ratio measures Freeline Therapeutics Holdings Plc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Freeline Therapeutics Holdings Plc’s operating margin was -12506.64% while its return on assets stood at -42.91% with a return of equity of -80.12%.
In Q2, Freeline Therapeutics Holdings Plc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Freeline Therapeutics Holdings Plc’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $-12.01 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Freeline Therapeutics Holdings Plc’s profitability.
Freeline Therapeutics Holdings Plc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of 0.1459. Its price to sales ratio in the trailing 12-months stood at 0.
Freeline Therapeutics Holdings Plc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $62.65 million
- Total Liabilities
- $18.68 million
- Operating Cash Flow
- Capital Expenditure
- Dividend Payout Ratio
Freeline Therapeutics Holdings Plc ended 2023 with $62.65 million in total assets and $0 in total liabilities. Its intangible assets were valued at $62.65 million while shareholder equity stood at $42.02 million.
Freeline Therapeutics Holdings Plc ended 2023 with $0 in deferred long-term liabilities, $18.68 million in other current liabilities, in common stock, $-460198000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $38.80 million and cash and short-term investments were $38.80 million. The company’s total short-term debt was $2,842,000 while long-term debt stood at $0.
Freeline Therapeutics Holdings Plc’s total current assets stands at $45.81 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $3.12 million compared to accounts payable of $6.88 million and inventory worth $1.06 million.
In 2023, Freeline Therapeutics Holdings Plc's operating cash flow was $0 while its capital expenditure stood at $256000.
Comparatively, Freeline Therapeutics Holdings Plc paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
Freeline Therapeutics Holdings Plc stock is currently trading at $3.52 per share. It touched a 52-week high of $13.488 and a 52-week low of $13.488. Analysts tracking the stock have a 12-month average target price of $12.8.
Its 50-day moving average was $3.94 and 200-day moving average was $5.7 The short ratio stood at 1.65 indicating a short percent outstanding of 0%.
Around 110.1% of the company’s stock are held by insiders while 6493.2% are held by institutions.
Frequently Asked Questions About Freeline Therapeutics Holdings Plc
Similar Industry Stocks (Biotechnology)
Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies. It develops FLT180a for the treatment of hemophilia B.; FLT201 for the treatment of Type 1 Gaucher disease; and FLT190 for the treatment of Fabry disease. in addition, it has research programs for systemic gene therapy. The company was founded in 2015 and is headquartered in Stevenage, the United Kingdom.